Current and Resolved Drug Shortages and Discontinuations Reported to FDA
Report a Drug Shortage |
FAQ |
Background Info |
Get Email Alerts |
Download Current Drug Shortages |
Contact Us
Start Over | Back to Previous Screen
Carboplatin Injection
Status: Currently in Shortage
»Date first posted:
04/28/2023
»Therapeutic Categories: Oncology
Accord Healthcare Inc. (Revised 11/04/2025)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34) | Limited Availability | non-Exempt status from FDA | Requirements related to complying with good manufacturing practices |
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12) | Available | ||
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33) | Unavailable | Discontinuation of the manufacture of the drug | Requirements related to complying with good manufacturing practices |
| Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31) | Unavailable | Discontinuation of the manufacture of the drug | Requirements related to complying with good manufacturing practices |
Eugia US LLC (Revised 10/17/2025)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01) | Available | Check wholesalers for inventory | |
| Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01) | Available | Check wholesalers for inventory |
Fresenius Kabi USA, LLC (Reverified 11/05/2025)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60) | Available | Check wholesalers for inventory |
Gland Pharma Limited (Reverified 09/29/2025)
Company Contact Information:
Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270
Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01) | Unavailable | Discontinued; Distributed by BPI Labs, LLC | Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01) | Limited Availability | Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC | Demand increase for the drug |
| Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01) | Limited Availability | Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC | Demand increase for the drug |
| Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01) | Limited Availability | Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC | Demand increase for the drug |
Hospira, Inc., a Pfizer Company (Revised 11/14/2025)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18) | Limited Availability | Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: December 2025 | Demand increase for the drug |
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18) | Limited Availability | Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: December 2025 | Other |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22) | Available | ||
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05) | Available | ||
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50) | Limited Availability | Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: December 2025 | Demand increase for the drug |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05) | Available | ||
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56) | Available | ||
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05) | Available |
Ingenus Pharmaceuticals LLC (Reverified 10/15/2025)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60) | Unavailable | For any other information, please contact the Ingenus Customer Service team at 866-321-5031. | Other |
| Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45) | Unavailable | For any other information, please contact the Ingenus Customer Service team at 866-321-5031. | Other |
Teva Pharmaceuticals USA, Inc. (Revised 11/06/2025)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01) | Available | ||
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01) | Available | ||
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01) | Available | ||
| Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01) | Available |
Teyro Labs (Reverified 11/05/2025)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1) | Unavailable | Discontinuation of the manufacture of the drug. | Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3) | Limited Availability | Discontinuation of the manufacture of the drug. | Discontinuation of the manufacture of the drug |
| Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6) | Limited Availability, Replenishment is expected 12/1/25 | Wholesaler & Distributor through Marketing partner (Apotex Inc.) | Demand increase for the drug |
| Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7) | Limited Availability, Replenishment is expected 12/1/25 | Wholesaler & Distributor through Marketing partner (Apotex Inc.) | Demand increase for the drug |